Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial
- 31 December 2003
- journal article
- review article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 9 (6) , 429-443
- https://doi.org/10.1016/j.cardfail.2003.08.003
Abstract
No abstract availableKeywords
This publication has 145 references indexed in Scilit:
- Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathyJournal of the American College of Cardiology, 2003
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized studyJournal of the American College of Cardiology, 1995
- Pharmacokinetic and Pharmacodynamic Evaluation of Metoprolol Controlled Release (CR/ZOK) 50 mg in Young SubjectsThe Journal of Clinical Pharmacology, 1990
- Pharmacokinetic and Pharmacodynamic Properties of Controlled Release (CR/ZOK) Metoprolol in Healthy Oriental Subjects: A Comparison with Conventional Formulations of Metoprolol and AtenololThe Journal of Clinical Pharmacology, 1990
- A Pharmacokinetic and Pharmacodynamic Comparison of Metoprolol CR/ZOK with a Conventional Slow Release PreparationThe Journal of Clinical Pharmacology, 1990
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985
- Diltiazem in the Treatment of Mild or Moderate Essential Hypertension. Comparison with Metoprolol in a Crossover Double‐Blind TrialThe Journal of Clinical Pharmacology, 1984
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981